论文部分内容阅读
本实验以复方茵栀四黄(6912)注射液(原方)为对照,对比观察两个不含黄连素组分的改进制剂(新方:6912-1,6912-3)对实验动物肝炎模型疗效。实验结果认为:(1) ANIT动物肝损伤模型,可用于护肝药物的研究;(2) 茵栀四黄注射液的退黄效果较好,且6912-3退黄效果优于6912,而6912-1则无退黄作用,可能与其中缺少黄连素或黄芩甙有关;(3) 本实验中降酶的效果不显著。从临床用药安全性考虑,用无黄连素的6912-3制剂可望代替6912注射液用于临床。
In this experiment, the compound Yinzhi Sihuang (6912) injection (the original prescription) was used as a control, and two modified preparations containing no berberine component (Xinfang: 6912-1, 6912-3) were used to compare experimental animal hepatitis models. Efficacy. The experimental results suggest that: (1) ANIT animal liver injury model can be used for the study of liver protection drugs; (2) Yinzhisihuang injection has good yellowing effect, and 6912-3 yellowing effect is better than 6912, and 6912 -1 has no yellowing effect, which may be related to the lack of berberine or jaundice; (3) The effect of reducing enzyme in this experiment is not significant. From the perspective of clinical drug safety, the 6912-3 preparation without berberine is expected to replace 6912 injection for clinical use.